US 12,077,601 B2
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
Michael Catania, San Diego, CA (US); and Ronald L. Hayes, San Diego, CA (US)
Assigned to BANYAN BIOMARKERS, INC., San Diego, CA (US)
Filed by Banyan Biomarkers, Inc., San Diego, CA (US)
Filed on Jul. 19, 2021, as Appl. No. 17/379,739.
Application 17/379,739 is a division of application No. 16/345,562, granted, now 11,078,298, previously published as PCT/US2017/058881, filed on Oct. 27, 2017.
Claims priority of provisional application 62/414,569, filed on Oct. 28, 2016.
Prior Publication US 2021/0347914 A1, Nov. 11, 2021
Int. Cl. C07K 16/40 (2006.01); A61B 5/00 (2006.01); A61B 5/055 (2006.01); A61B 6/03 (2006.01); A61B 6/50 (2024.01); A61P 25/00 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01); A61B 6/00 (2024.01)
CPC C07K 16/40 (2013.01) [A61B 5/0042 (2013.01); A61B 5/055 (2013.01); A61B 6/032 (2013.01); A61B 6/501 (2013.01); A61P 25/00 (2018.01); C07K 16/18 (2013.01); G01N 33/6896 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An antibody or antigen-binding fragment thereof that specifically binds to a human ubiquitin c-terminal hydrolase L1 (UCH-L1) protein, comprising:
a heavy chain variable region that comprises CDR-H1, CDR-H2, and CDR-H3 amino acid sequences; and
a light chain variable region that comprises CDR-L1, CDR-L2, and CDR-L3 amino acid sequences,
wherein:
(1) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:2, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:10, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:21; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:29, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:38, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:46; or
(2) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:5, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:13, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:23; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:32, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:39, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:47; or
(3) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:3, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:11, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:20; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:30, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:37, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:45; or
(4) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:4, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:12, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:22; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:31, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:39, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:47; or
(5) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:6, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:14, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:24; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:33, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:40, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:48; or
(6) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:6, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:14, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:24; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:34, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:41, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:48; or
(7) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:6, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:15, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:24; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:34, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:42, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:48; or
(8) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:6, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:14, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:24; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:35, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:41, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:48; or
(9) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:6, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:16, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:25; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:34, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:42, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:48; or
(10) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:7, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:17, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:26; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:36, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:43, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:49; or
(11) the heavy chain variable region comprises (i) the CDR-H1 amino acid sequence comprising SEQ ID NO:8, (ii) the CDR-H2 amino acid sequence comprising SEQ ID NO:18, and (iii) the CDR-H3 amino acid sequence comprising SEQ ID NO:27; and
the light chain variable region comprises (i) the CDR-L1 amino acid sequence comprising SEQ ID NO:36, (ii) the CDR-L2 amino acid sequence comprising SEQ ID NO:44, and (iii) the CDR-L3 amino acid sequence comprising SEQ ID NO:49.